Drugs / Sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07261098 | Jan 2026 → Dec 2027 expected | lung cancer | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/valsartan | “Sacubitril/valsartan, a combination of an angiotensin II receptor blocker and neprilysin inhibitor (ARNI), is a novel agent to treat HF and has been approved to treat...” NCT07261098 ↗ |
| Action | Inhibit | “angiotensin II receptor blocker and neprilysin inhibitor” NCT07261098 ↗ |